Caribou Biosciences: FDA Grants Fast Track Designation To CB-011

Caribou Biosciences, Inc. (CRBU) announced the FDA has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma.

Related Keywords

Syed Rizvi ,More Such Health News ,Caribou Biosciences Inc ,Caribou Biosciences ,Fast Track ,Fda ,Cb 011 ,